|Bid||39.10 x 1000|
|Ask||39.27 x 1100|
|Day's range||39.18 - 39.78|
|52-week range||31.43 - 48.25|
|Beta (5Y monthly)||0.36|
|PE ratio (TTM)||39.58|
|Forward dividend & yield||1.89 (4.79%)|
|Ex-dividend date||14 May 2020|
|1y target est||N/A|
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.
* The Phase 3 study is evaluating the safety, tolerability and immunogenicity of GSK's MenABCWY vaccine candidate compared to BEXSERO and MENVEO in adolescents and young adults * Study investigators to enrol 3,650 participants aged 10-25 years in Canada, the U., Europe, Turkey and AustraliaMISSISSAUGA, ON, Aug.
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.